Literature DB >> 33049683

Nanog promotes stem-like traits of glioblastoma cells.

Ye Yuan1, Mengsi Zhang1, Guangning Yan2, Qinghua Ma1, Zexuan Yan1, Lihong Wang1, Kaidi Yang1, Deyu Guo3.   

Abstract

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with poor progrnosis and a high recurrence rate after surgery. To this end, we examined the role of Nanog that is highly expressed in this tumor. NANOG is a transcription factor involved in the pluripotency of embryonic stem cells (ESCs) and the induction of malignancy in cancer stem-like cells (CSCs). Bioinformatic analysis revealed that NANOG may be associated with the development of stem-like traits in GBM. Forced expression of NANOG markedly increased the expression of cancer stem cell markers and promoted the sphere formation and migration of GBM cells. Nanog enhanced the expression of SHH which is required for the maintenance of the positive feedback loop of Hedgehog signaling pathway. Treatment of GBM cells with SANT-1 and GANT61 significantly reduced the tumor progression. These data support a view that reduction of Nanog might have therapeutic benefits in GBM.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33049683     DOI: 10.2741/4907

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  3 in total

Review 1.  Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives.

Authors:  Marc-Antoine Da-Veiga; Bernard Rogister; Arnaud Lombard; Virginie Neirinckx; Caroline Piette
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

Review 2.  Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms.

Authors:  Emanuela B Pucko; Robert P Ostrowski
Journal:  Pharmaceutics       Date:  2022-01-30       Impact factor: 6.321

Review 3.  Hedgehog signaling regulates the development and treatment of glioblastoma.

Authors:  Hongping Wang; Qun Lai; Dayong Wang; Jian Pei; Baogang Tian; Yunhe Gao; Zhaoguo Gao; Xiang Xu
Journal:  Oncol Lett       Date:  2022-07-05       Impact factor: 3.111

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.